Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis

Garre, Elisa García; Luengo‐Gil, Ginés; Garcia, S.; Billalabeitia, E. González; Poves, Marta Zafra; Martínez, Elena García; Schilling, V; Manzano, Esther Navarro; Rubio, Alejandra Ivars; Lip, Gregory Y.H.; Peña, Francisco Ayala de la

doi:10.1007/s10549-017-4656-z

Cited by 16 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be explained by the additional presence of EMMPRIN on platelet-and immune cell-derived MV [11], which are directly influenced by the surgery. Prolonged high levels of total EV or endothelial cell-derived CD144+ MV after chemotherapy seem to predict a poor clinical response and were found to be associated with shorter progression-free and overall survival [134,135]. The same trend was observed in glioblastoma patients showing tumor progression after radiochemotherapy who generally exhibited higher MV levels compared with patients with pseudoprogression or stable disease [136].…”

Section: For Therapy Monitoringmentioning

confidence: 83%

Microvesicles in Cancer: Small Size, Large Potential

Menck

Sivaloganathan

Bleckmann

et al. 2020

IJMS

View full text Add to dashboard Cite

Extracellular vesicles (EV) are secreted by all cell types in a tumor and its microenvironment (TME), playing an essential role in intercellular communication and the establishment of a TME favorable for tumor invasion and metastasis. They encompass a variety of vesicle populations, among them the well-known endosomal-derived small exosomes (Exo), but also larger vesicles (diameter > 100 nm) that are shed directly from the plasma membrane, the so-called microvesicles (MV). Increasing evidence suggests that MV, although biologically different, share the tumor-promoting features of Exo in the TME. Due to their larger size, they can be readily harvested from patients’ blood and characterized by routine methods such as conventional flow cytometry, exploiting the plethora of molecules expressed on their surface. In this review, we summarize the current knowledge about the biology and the composition of MV, as well as their role within the TME. We highlight not only the challenges and potential of MV as novel biomarkers for cancer, but also discuss their possible use for therapeutic intervention.

show abstract

Section: For Therapy Monitoringmentioning

confidence: 83%

Microvesicles in Cancer: Small Size, Large Potential

Menck

Sivaloganathan

Bleckmann

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…However, a research has shown that lower levels of ECs-derived microvesicles are related to better survival after chemotherapy in breast cancer patients, suggesting that ECs-derived exosomes also might have an important influence on tumor progression. 73 …”

Section: Exosome-mediated Metabolic Reprogramming In the Tmementioning

confidence: 99%

Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression

Yang

Wang

Gong

et al. 2020

Sig Transduct Target Ther

267

185

View full text Add to dashboard Cite

Metabolic reprogramming is reported to be one of the hallmarks of cancer, which is an adaptive mechanism by which fast-growing cancer cells adapt to their increasing energy demands. Recently, extracellular vesicles (EVs) known as exosomes have been recognized as crucial signaling mediators in regulating the tumor microenvironment (TME). Meanwhile, the TME is a highly heterogeneous ecosystem incorporating cancer cells, fibroblasts, adipocytes, endothelial cells, mesenchymal stem cells, and extracellular matrix. Accumulated evidence indicates that exosomes may transfer biologically functional molecules to the recipient cells, which facilitate cancer progression, angiogenesis, metastasis, drug resistance, and immunosuppression by reprogramming the metabolism of cancer cells and their surrounding stromal cells. In this review, we present the role of exosomes in the TME and the underlying mechanism of how exosomes exacerbate tumor development through metabolic reprogramming. In addition, we will also discuss the potential role of exosomes targeting metabolic process as biomarkers for tumor diagnosis and prognosis, and exosomes-mediated metabolic reprogramming as potential targets for cancer therapy. Furthermore, a better understanding of the link between exosomes and metabolic reprogramming, and their impact on cancer progression, would provide novel insights for cancer prevention and treatment in the future.

show abstract

“…Aharon et al observed that microvesicles which bore MMP played a key role in angiogenesis and were involved in EC invasion and capillary formation (11). It is suggested that EMPs might be indicators of prognosis in patients with cancer (12,23). Consequently, the exact role of EMPs in cancer, and particularly in angiogenesis, needs to be further investigated.…”

Section: Discussionmentioning

confidence: 99%

Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy

Sierko

Sobierska

Zabrocka

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background: Endothelial microparticles (EMPs) released from activated or apoptotic endothelial cells may play a role in coagulation and thrombus formation. However, there is insufficient evidence regarding the impact of EMPs on angiogenesis in patients with cancer. Materials and Methods: Sixteen patients with head and neck cancer (HNC) undergoing radiotherapy/radiochemotherapy (RT/RCT) and 10 healthy controls were studied. Serum EMPs were counted by flow cytometry, and vascular endothelial growth factor (VEGF) was measured by enzymelinked immunosorbent assay (ELISA). Results: The mean EMP level was significantly higher in patients with HNC before RT/RCT (1,601±1,479 EMP/μl) compared to the control group (782±698 EMP/μl). The number of EMPs was not notably increased after RT/RCT (1,629±769 EMP/μl). There was no significant correlation between the plasma EMP number and concentration of VEGF before (r=0.131; p=0.625), 1 day after (r=−0.042, p=0.874), nor 3 months after RT/RCT (r=0.454, p=0.076). Conclusion: Released EMPs may not influence promotion of neovascularization in patients with HNC. Endothelial microparticles (EMPs) are vesicular structures with a diameter from 1 to 2 μm which are shed from activated or apoptotic endothelial cells (ECs) (1). The density of EMPs in the blood of healthy individuals ranges from 1-70×10 3 /ml (1). Knowledge about EMP formation has been obtained from experiments conducted on isolated or cultured ECs, whereas in vivo mechanisms involved in EMP generation still remain unclear. Inflammatory cytokines [e.g. tumor necrosis factor-α, (TNF-α)] bacterial lipopolysaccharides, reactive oxygen species, thrombin, camptothecin and chemotherapy were reported to induce EMP generation (1, 2). EMPs express a large variety of molecules representative of their parent cells (3). Their composition differs depending on the cells they originate from and the type of stimulus leading to their formation (4). On their surface, EMPs bear phospholipids, membrane receptors such as endothelial protein C receptor, thrombomodulin, tissue factor, adhesion molecules such as intercellular cell adhesion molecule-1, platelet-EC adhesion molecule, endothelial selectin and P-selectin (3). In addition, EMPs harbor enzymes such as matrix metalloproteinase, nicotinamide adenine dinucleotide phosphate oxidase, urokinase plasminogen activator and its receptor, and growth factor receptors (3). The density of EMPs is elevated in various clinical settings. Activated or apoptotic EC-derived EMPs are a marker of endothelial damage and their level was found to be increased in the blood of obese women, patients with terminal stage renal failure or multiple sclerosis (5-7). Moreover, it has been documented that EMPs contribute to initiation of blood coagulation and support thrombus formation (3, 8, 9). Furthermore, a higher level of EMPs was found in patients with hematological disorders e.g. lupus anticoagulant, sickle cell disease, anti-phospholipid syndrome and venous thromboembolism, than in healthy individuals (3, 9, 10). In ...

show abstract

Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis

Cited by 16 publications

References 32 publications

Microvesicles in Cancer: Small Size, Large Potential

Microvesicles in Cancer: Small Size, Large Potential

Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression

Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy

Contact Info

Product

Resources

About